These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 24008655)
1. Carvedilol enhances the antioxidant effect of vitamins E and C in chronic Chagas heart disease. Budni P; Pedrosa RC; Dalmarco EM; Dalmarco JB; Frode TS; Wilhelm Filho D Arq Bras Cardiol; 2013 Oct; 101(4):304-10. PubMed ID: 24008655 [TBL] [Abstract][Full Text] [Related]
2. Carvedilol attenuates oxidative stress in chronic chagasic cardiomyopathy. Budni P; Pedrosa RC; Garlet TR; Dalmarco EM; Dalmarco JB; Lino MR; Simionato EL; Amara JA; Frode TS; Wilhelm Filho D Arq Bras Cardiol; 2012 Mar; 98(3):218-24. PubMed ID: 22344676 [TBL] [Abstract][Full Text] [Related]
4. Impact of the Use of Benznidazole Followed by Antioxidant Supplementation in the Prevalence of Ventricular Arrhythmias in Patients With Chronic Chagas Disease: Pilot Study. Barbosa JL; Thiers CA; de Bragança Pereira B; do Nascimento EM; Ribeiro Frazon CM; Budni P; Wilhelm Filho D; Pedrosa RC Am J Ther; 2016; 23(6):e1474-e1483. PubMed ID: 25461962 [TBL] [Abstract][Full Text] [Related]
5. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. Bajcetic M; Kokic Nikolic A; Djukic M; Kosutic J; Mitrovic J; Mijalkovic D; Jovanovic I; Simeunovic S; Spasic MB; Samardzic R Clin Ther; 2008 Apr; 30(4):702-14. PubMed ID: 18498919 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of antioxidant therapy in experimental Chagas disease. Tieghi TM; Manca CC; Garcia LCT; Castanho REP; Therezo ALS; Frei F; Taipeiro EF; Martins LPA Rev Soc Bras Med Trop; 2017; 50(2):184-193. PubMed ID: 28562754 [TBL] [Abstract][Full Text] [Related]
7. Carvedilol decreases elevated oxidative stress in human failing myocardium. Nakamura K; Kusano K; Nakamura Y; Kakishita M; Ohta K; Nagase S; Yamamoto M; Miyaji K; Saito H; Morita H; Emori T; Matsubara H; Toyokuni S; Ohe T Circulation; 2002 Jun; 105(24):2867-71. PubMed ID: 12070115 [TBL] [Abstract][Full Text] [Related]
8. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. Castro P; Vukasovic JL; Chiong M; Díaz-Araya G; Alcaino H; Copaja M; Valenzuela R; Greig D; Pérez O; Corbalan R; Lavandero S Eur J Heart Fail; 2005 Oct; 7(6):1033-9. PubMed ID: 16227141 [TBL] [Abstract][Full Text] [Related]
9. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. Farias MS; Budni P; Ribeiro CM; Parisotto EB; Santos CE; Dias JF; Dalmarco EM; Fröde TS; Pedrosa RC; Wilhelm Filho D Gastroenterol Hepatol; 2012; 35(6):386-94. PubMed ID: 22608494 [TBL] [Abstract][Full Text] [Related]
10. Antioxidant intervention attenuates oxidative stress in children and teenagers with Down syndrome. Parisotto EB; Garlet TR; Cavalli VL; Zamoner A; da Rosa JS; Bastos J; Micke GA; Fröde TS; Pedrosa RC; Wilhelm Filho D Res Dev Disabil; 2014 Jun; 35(6):1228-36. PubMed ID: 24685938 [TBL] [Abstract][Full Text] [Related]
11. Antioxidant potential of vitamins A, E and C in modulating oxidative stress in rat brain. Zaidi SM; Banu N Clin Chim Acta; 2004 Feb; 340(1-2):229-33. PubMed ID: 14734217 [TBL] [Abstract][Full Text] [Related]
12. Carvedilol and antioxidant proteins in a type I diabetes animal model. Diogo CV; Deus CM; Lebiedzinska-Arciszewska M; Wojtala A; Wieckowski MR; Oliveira PJ Eur J Clin Invest; 2017 Jan; 47(1):19-29. PubMed ID: 27805735 [TBL] [Abstract][Full Text] [Related]
13. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478 [TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Kukin ML; Kalman J; Charney RH; Levy DK; Buchholz-Varley C; Ocampo ON; Eng C Circulation; 1999 May; 99(20):2645-51. PubMed ID: 10338457 [TBL] [Abstract][Full Text] [Related]
15. The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure. Karabacak M; Dogan A; Tayyar S; Bas HA Kardiol Pol; 2015; 73(3):201-6. PubMed ID: 25299401 [TBL] [Abstract][Full Text] [Related]
16. Immunopharmacological approach of carvedilol in chronic Chagas heart disease. Miranda CP; Botoni FA; Rocha MO Arq Bras Cardiol; 2014 Oct; 103(4):358. PubMed ID: 25352510 [No Abstract] [Full Text] [Related]
17. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Ruffolo RR; Feuerstein GZ Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017 [TBL] [Abstract][Full Text] [Related]
18. Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. Troncoso R; Moraga F; Chiong M; Roldán J; Bravo R; Valenzuela R; Díaz-Araya G; del Campo A; Sanhueza C; Rodriguez A; Vukasovic JL; Mellado R; Greig D; Castro PF; Lavandero S Basic Clin Pharmacol Toxicol; 2009 May; 104(5):374-8. PubMed ID: 19422106 [TBL] [Abstract][Full Text] [Related]
19. Antioxidant therapy attenuates oxidative stress in chronic cardiopathy associated with Chagas' disease. Maçao LB; Wilhelm Filho D; Pedrosa RC; Pereira A; Backes P; Torres MA; Fröde TS Int J Cardiol; 2007 Dec; 123(1):43-9. PubMed ID: 17328977 [TBL] [Abstract][Full Text] [Related]